BioLineRx Announces Closing of $15.4 Million Underwritten Publ...
TEL AVIV, Israel, Feb. 8, 2019 /PRNewswire-AsiaNet/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it has closed its previously announced underwritten public offering of 28,000,000 American Depositary Shares ("...
Authors: LATEST ASIANET NEWS RELEASES